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Abstract 
Highly conserved TREX-mediated mRNA export is emerging as a key pathway in neuronal 
development and differentiation. TREX subunit variants cause perturbed mRNA export from 
the cell nucleus to the cytoplasm and lead to neurodevelopmental disorders (NDDs). Our 
previous work implicated the THOC2 gene on the X-chromosome in intellectual disability 
(ID). Borderline to severe ID with speech delay, behavioural problems, short stature, elevated 
BMI and truncal obesity in adulthood were observed. We now report an additional six 
affected individuals from five unrelated families with pathogenic or likely pathogenic 
variants in THOC2, two de novo and three maternally-inherited, extending the genotypic and 
phenotypic spectrum. These comprise three rare missense THOC2 variants that affect 
evolutionarily conserved amino acid residues and reduce protein stability and affected males 
from two families with canonical splice-site THOC2 variants that result in C-terminally 
truncated THOC2 proteins. We present detailed clinical assessment and functional studies on 
a de novo variant in a female with an epileptic encephalopathy and discuss an additional four 
families with rare variants in THOC2 with supportive evidence for pathogenicity. Severe 
neurocognitive features, including movement and seizure disorders were observed in this 
expanded cohort. Taken together, our data significantly expand existing evidence showing 
that even subtle alterations to the canonical molecular pathways such as mRNA export, 
otherwise essential for cellular life, can be compatible with life, but lead to NDDs in humans.  
 
 
KEY WORDS 
XLID; THOC2; mRNA export; protein stability; partial loss-of-function variants   
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INTRODUCTION 
Intellectual disability (ID), characterized by substantial limitations in both intellectual 
functioning and adaptive behaviour, affects 1-3% of the population starting before the age of 
18 years and has significant impact on individuals, families and communities (Vissers, et al., 
2016). Individuals with ID are more likely than members of the general population to 
experience poor physical and mental health, have a lower life expectancy, experience 
inequalities accessing health care and frequently have limited or no specific therapies for 
their core symptoms (Bittles, et al., 2002; Hosking, et al., 2016). Both genetic and 
environmental factors contribute to the development of ID (Milani, et al., 2015). Over 130 of 
the identified >800 ID genes are located on the X-chromosome, and diagnosis of X-linked 
causes of ID remain critically important for accurate genetic counseling of families (Ropers 
and Hamel, 2005). Dramatic improvements in high-throughput DNA sequencing 
technologies and analyses software has led to identification/discovery of new ID genes and 
additional variants in the known ID genes (Dickinson, et al., 2016; Vissers, et al., 2016). A 
systematic review of clinical data suggests that ID affected individuals commonly have 
comorbid neurological, psychiatric and behavioural disorders (Oeseburg, et al., 2011; 
Vissers, et al., 2016), and disease variants in different parts of a gene can lead to a broad 
range of complex neurocognitive disorders (Palmer, et al., 2017; Zhu, et al., 2014). This 
complexity contributes to heterogeneity in clinical symptoms and indistinct boundaries 
between syndromic and non-syndromic forms of NDD. 
 
In 2015, we reported genetic, molecular and protein structural data on four missense variants 
in an X-linked essential gene THOC2 (NM_001081550.1: p.Leu313Phe, p.Leu438Pro, 
p.Ile800Thr and p.Ser1012Pro) (Kumar, et al., 2015). The affected individuals had a 
syndromic NDD, characterized by borderline to severe ID, speech delay, short stature and 
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adult onset truncal obesity (Kumar, et al., 2015). THOC2 encodes for the THOC2 protein - 
the largest subunit of the highly conserved TREX (Transcription-Export) mRNA export 
complex essential for exporting mRNA from the cell nucleus to the cytoplasm (Heath, et al., 
2016). The TREX complex is composed of a THO sub-complex (THOC1, THOC2, THOC3, 
THOC5 and THOC7) and accessory proteins (UAP56, UIF, Aly, CIP29, PDIP3, ZC11A, 
SRRT, Chtop) (Heath, et al., 2016). The TREX complex, besides its canonical role in mRNA 
export in the mammalian cells, has been shown to perform critical roles in gene expression, 
3’ mRNA processing, stress responses, mitotic progression and genome stability as well as 
developmental processes such as pluripotency maintenance and hematopoiesis (Yamazaki, et 
al., 2010). We and others have recently demonstrated that subtle perturbations in mRNA 
export by gene variants or preferential cytoplasmic aggregation can lead to NDDs (Beaulieu, 
et al., 2013; Coe, et al., 2014; Kumar, et al., 2015), neurodegeneration (Woerner, et al., 2016) 
or cancer (Chinnam, et al., 2014; Hautbergue, 2017; Liu, et al., 2015; Viphakone, et al., 
2015). These alterations can have tissue-specific effects as TREX subunits are shown to have 
tissue-specific roles; for example, mouse Thoc5 deficiency interferes with the maintenance of 
hematopoiesis (Guria, et al., 2011; Mancini, et al., 2010) and Thoc1 deficiency interferes with 
testis development (Wang, et al., 2009). Taken together, altered TREX function can have 
diverse molecular and cellular consequences resulting in a range of diseases. Here we present 
detailed information on the clinical presentations and functional investigations on an 
additional eight missense and two splice THOC2 variants. These data reaffirm and extend our 
previous findings that THOC2 variation is responsible for causing complex 
neurodevelopmental conditions with the core clinical presentation of ID.    
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MATERIALS AND METHODS 
Molecular and cellular studies 
RNA extraction, RT-qPCR (primers listed in Supp. Table S1), cycloheximide chase, and 
THOC2 immunofluorescence staining were performed as reported previously (Kumar, et al., 
2015). Molecular studies on the THOC2 exon35:c.4450-2A>G variant were performed using 
blood DNA and skin fibroblasts derived from the affected individual and his heterozygous 
carrier mother. Genomic DNA or cDNA was amplified with KAPA HiFi PCR Kit (Kapa 
Biosystems) using hTHOC2-4326F/ hTHOC2-4519-R (Supp. Table S1) at 95°C for 3 min, 
35 cycles of 98°C-15sec, 59°C-15sec, 72°C-30sec, incubation at 72°C for 10 min, gel 
purified (MinElute Gel Extraction kit (Qiagen) and Sanger sequenced using the same 
primers. For the THOC2 exon28:c.3503+4A>C, blood gDNA from unaffected father, carrier 
mother and affected son was amplified with TaKaRa ExTaq using THOC2-F/THOC2-R 
primers (Supp. Table S1) at 94°C for 2 min, 40 cycles of 94°C-30sec, 60°C-30sec, 72°C-
30sec, incubation at 72°C for 5 min. The cDNA was generated by reverse transcribing the 
white blood cell RNAs using Superscript III reverse transcriptase (Life Technologies) and 
amplified with TaKaRa ExTaq using THOC2-ex27F/THOC2-ex30R (Supp. Table S1) at 
94°C for 2 min, 28 cycles of 94°C-30sec, 60°C-30sec, 72°C-30sec, incubation at 72°C for 5 
min. The amplified products were analyzed by Sanger sequencing. 
 
Generation of THOC2 variant expression constructs 
Generation of the wild type Myc-tagged human THOC2 expression plasmid was reported 
earlier (Kumar, et al., 2015). Briefly, the THOC2 variants were introduced into the existing 
pCMV-Myc-THOC2 expression construct by overlap PCR method using the primers listed in 
Supp. Table S1. The variant plasmid sequences were confirmed by Sanger sequencing. 
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Details relating generation of the THOC2 variant expression constructs are available on 
request. 
 
Transient expression and Western blotting 
For transient expression experiments, HEK293T and HeLa cells were transfected with 
expression constructs (400ng pCMV-Myc-THOC2 plasmid and 400ng pEGFP-C1 
plasmid/transfection for stability and cycloheximide assays and 4µg/transfection for 
immunofluorescence staining, IF) using Lipofectamine 3000 reagent according to 
manufacturer’s protocol (Life technologies). Twenty-four hours post-transfection, cells were 
either fixed with 4% formaldehyde for IF or collected and lysed in buffer containing 50 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Triton-X 100, 1 mM EDTA, 50 mM NaF, 1× Protease 
inhibitor/no EDTA and 0.1 mM Na3VO4 for western blot assay as reported previously 
(Kumar, et al., 2015). 
 
RESULTS 
Identification of THOC2 variants 
We previously implicated four missense THOC2 variants in 25 individuals with ID and a 
range of other clinical features (Table 1) (Kumar, et al., 2015). We identified an additional 
five THOC2 variants (three missense; de novo p.Thr696Ile, de novo p.Gly713Asp, 
maternally-inherited p.His1187Tyr, and two splicing-defective; maternally-inherited 
chrX:122747409 exon35:c.4450-2A>G and chrX:122757634 exon28:c.3503+4A>C; 
GenBank: NM_001081550.1) variants in a further six affected individuals, including one pair 
of monozygotic twins (Table 1, Figures 1-2). Whole exome (WES) or whole genome 
sequencing (WGS) of probands and parents was used to identify the variants that were 
confirmed by Sanger sequencing of the PCR amplified variant-carrying region of genomic 
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DNA of the parents and affected individuals. The previously unreported THOC2 variants 
affect amino acids that are highly conserved (Supp. Figure S1), are absent in gnomAD 
database and are predicted to be pathogenic based on a number of in silico prediction criteria 
(Table 1). We also included in our study a de novo missense p.Tyr517Cys variant in a female 
with moderate-severe ID, speech problems, epileptic encephalopathy, cortical visual 
impairment, and gait disturbances identified using WES as part of the Epi4K Consortium & 
Epilepsy Phenome/Genome Project (Epi, et al., 2013) (Table 1).  We have also collected 
further, rare and potentially pathogenic variants through international collaboration (Table1, 
Figures 1 and 3) and performed functional testing on several of these. The following three 
variants: p.Arg77Cys, p.Ser1012Pro and p.Asn1261His showed no clear evidence of altered 
stability of variant THOC2 proteins in our assay.  
 
Clinical presentations  
The clinical features of the five previously unreported affected individuals with (likely) 
pathogenic THOC2 variants, aged between 3 and 12 years, and the 10 year old female with de 
novo p.Tyr517Cys variant are summarised in Table 2 and photographs, when available, are 
shown in Figure 2. Detailed clinical information is available in the supplementary data. ID 
was universal and at least moderate in severity: 2/7 were non-ambulatory and 3/7 non-verbal. 
Behavioural problems were reported in four individuals, with one meeting diagnostic criteria 
for autism spectrum disorder. Common additional neurological features include infantile 
hypotonia (4/7), tremor (2/7) and gait disturbance including balance problems/ataxia and toe 
walking (4/5 ambulatory individuals). Confirmed seizure disorder was only present in the 
affected female (individual 7) but suspected in individual 2. Neuro-radiological studies were 
performed in five individuals and reported as abnormal in three (available data presented in 
Supp. Figure S2). Growth abnormalities were common including low birth weight (3/7), 
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microcephaly (2/7) and short stature (2/7). Facial features are shown in Figure 2. Appropriate 
consent for reporting variants, clinical data and photographs of the affected individuals was 
obtained from their parents or legal guardians. The research has been approved by the 
Women’s and Children’s Health Network Human Research Ethics Committee in Adelaide, 
Australia. 
 
THOC2 variant protein localisation and stability 
Without access to affected individuals' derived cells, we generated Myc-tagged THOC2 
missense variant expression constructs to determine protein stability and localisation. The 
THOC2 protein stability was determined in HEK293T cells and localisation in both the 
HEK293T and HeLa cells. Total protein lysates of HEK293T cells ectopically-expressing the 
wild type or variant Myc-THOC2 proteins were western blotted for THOC2, EGFP and β-
Tubulin. We used HEK293T cells expressing Myc-p.Ile800Thr THOC2 as a control for 
protein stability assay as this variant is shown to cause reduced protein stability (Kumar, et 
al., 2015). The results showed reduced stability of p.Tyr517Cys, p.Thr696Ile, p.Gly713Asp 
and p.His1187Tyr THOC2 compared to the wild type protein (Figure 3A). Presence of 
comparable levels of EGFP in the cells transfected with different expression constructs 
indicated that the reduced levels of THOC2 protein were not due to difference in transfection 
efficiency (Figure 3). We also determined the turnover rate of Myc-p.Tyr517Cys THOC2 
protein by cycloheximide chase. For this assay, the HEK293T cells transfected with pCMV-
Myc-WT or pCMV-Myc-p.Tyr517Cys THOC2 and pEGFP-C1 transfection control plasmids 
were cultured in presence of translation inhibitor cycloheximide for different durations and 
western blotted for THOC2, EGFP and β-Tubulin. The results showed that p.Tyr517Cys 
THOC2 turnover rate was 3h compared with 8h for the wild type protein (Figure 3B). 
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THOC2 variant proteins, similar to the wild type, were mainly localised to the nucleus in 
both the HEK293T and HeLa cells (Supp. Figure S3). 
 
THOC2 splice variant: exon35:c.4450-2A>G 
Sanger sequencing of amplified target region from affected son and mother's blood genomic 
DNA showed that the affected boy inherited chrX:122747409 exon35:c.4450-2A>G variant 
from his unaffected heterozygous carrier mother (Figure 4C). A -2 A>G change in the intron-
exon splicing site boundary (acceptor AG) is predicted to abolish splicing (Ohno, et al., 
2017). To validate this possibility, we generated skin fibroblast cultures from the 
heterozygous carrier mother and the affected son. We PCR amplified their fibroblast cDNAs 
using primers with binding sequences located within exon 34 and 35. Amplification of a 194 
bp DNA fragment from the mother indicated normal splicing but a 537 bp product from the 
affected son indicated retention of the intron located between these exons (Figure 4A-B). We 
confirmed this result by Sanger sequencing of the PCR products generated from genomic 
DNA that showed presence of A/G nucleotides in the carrier mother but only G (A>G) 
nucleotide in the affected son (Figure 4C). The cDNA sequence showed presence of 
normally-spliced mRNA in the mother but retention of intronic sequence upstream of the 
exon 35 in the affected son indicating defective splicing due to presence of -2 G variant at the 
intron-exon 35 junction sequence (Figure 4C). The presence of normally-spliced mRNA in 
the unaffected mother is consistent with X-inactivation (94% skewing) of the variant allele in 
her fibroblasts. We predicted that a retention of intron between exon 34-35 in the affected 
fibroblasts would result in loss of 110 C-terminal amino acids of the 1593 wild type THOC2 
protein (that is, 1483 amino acids); however, overall the variant protein would be 58 amino 
acid smaller as it would now be a 1535 amino acid protein comprised of 1483 amino acids of 
wild type THOC2 and 52 translated from intronic sequence in the pre-mRNA (Figure 1A). 
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Consistent with our prediction, the western blot data showed presence of a slightly smaller 
THOC2 protein band in the affected son’s fibroblasts than his unaffected mother. Many 
independent western blot runs showed presence of two closely-located THOC2 bands - 
similar to the fruit fly THO2 (Rehwinkel, et al., 2004) - in the unaffected mother but a single 
highly intense band in the affected son’s fibroblasts (Figure 4D). The observed difference in 
levels of THOC2 protein was post-translational as we found comparable amounts of THOC2 
mRNA, as assayed by real time RT-qPCR, in the mother and son (Figure. 4E). Finally, we 
observed no difference in THOC2 localisation in fibroblasts of the affected son and his 
unaffected mother (Figure 4F). 
 
THOC2 splice variant: exon28:c.3503+4A>C 
For the second splice variant chrX:122757634 exon28:c.3503+4A>C, molecular studies were 
performed on the white blood cells of the unaffected father, carrier mother and the male 
proband. Sanger sequencing of target region amplified from the unaffected father and mother, 
and affected son's genomic DNA showed that the affected son inherited the A>C change 
from his unaffected carrier mother who had A/C nucleotides at this position (Figure 5). The 
intronic nucleotide change A>C at +4 position of the 5' exon-intron donor splicing site 
sequence is predicted to cause aberrant splicing (https://www.med.nagoya-
u.ac.jp/neurogenetics/SD_Score/sd_score.html). To confirm this possibility, we amplified 
cDNA generated by reverse transcribing blood RNA of the father, mother and the affected 
son using primers located within exon 27 and exon 30 (Figure 5A; Supp. Table S1). 
Interestingly, whereas a 491 bp PCR product was observed in highly skewed carrier mother 
(98:2%) and normal father, 491 bp and 634 bp PCR products were detected in the affected 
son. A 491 bp amplified product indicated normal splicing in the mother and father, and 491 
bp and 634 bp bands suggested partially-defective splicing in the affected son. Amplification 
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of a 634 bp instead of a 994 bp fragment that would have resulted from a complete retention 
of intron 28 indicated aberrant splicing event in the affected son (Figure 5). Sanger 
sequencing of 491 bp and 634 bp PCR products from the mother, father and son confirmed 
normal splicing in the mother and father and aberrant splicing in the affected son. The 
sequence showed retention of a 143 bp instead of complete 503 bp fragment due to activation 
of a cryptic splice site within the intron 28 in the son (Figure 5). Retention of 143 bps from 
intron 28 in the mRNA is predicted to result in a truncated THOC2 protein containing 1168 
wild type amino acids and 7 novel amino acids from the translation of the intronic sequence 
retained in the defective mRNA, which would be present in addition to the wild type 1593 
amino acid protein from the normally-spliced mRNA in the affected son.   
 
Discussion 
We present here detailed clinical information, and molecular and functional studies, on five 
previously unreported THOC2 variants in six affected males (two de novo variants and one 
maternally inherited variant in monozygotic twins) and on one affected female with a 
previously reported de novo p.Tyr517Cys variant. We present evidence that extends the 
genotypic spectrum beyond the four THOC2 missense variants that we reported previously 
(Kumar, et al., 2015) by including two intronic variants that affect splicing, and four missense 
variants that affect protein stability in a cell-based assay system. All of the variants meet 
ACMG criteria for pathogenic or likely pathogenic status (Table 1) (Richards, et al., 2015). 
These findings, along with the four missense variants reported earlier (Kumar, et al., 2015) 
add to the existing evidence that alterations in essential mRNA export pathway can cause 
NDDs (Amos, et al., 2017; Beaulieu, et al., 2013; Kumar, et al., 2015).  
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We confirm that the core clinical feature of THOC2-related disorder in hemizygous males is 
ID, with several individuals having additional neurocognitive features including infantile 
hypotonia, behavioural disorders and autism spectrum disorder, and (less commonly) gait 
disturbance and tremor. Although the range of neurodevelopmental features is similar, our 
original cohort contained males with borderline to mild ID (Kumar, et al., 2015); whereas, all 
individuals in this cohort have at least moderate ID. Five of the affected individuals had 
neuroimaging, with three having evidence of white matter thinning or cortical atrophy, and 
one individual (individual 2) having extensive cortical gyral abnormalities. Similarly, in the 
original cohort four of the six individuals with neuroimaging available were reported to have 
a variety of abnormalities including inferior cerebellar vermis dysplasia, ventriculomegaly, 
gliosis and mild cervical cord compression. A consistent pattern of extra-neurological 
features was not evident, although as in the original cohort, several individuals had evidence 
of restricted growth, including short stature, low birth weight and microcephaly. The truncal 
obesity, raised BMI and co-morbid anxiety and depression frequently noted in the original 
cohort was not observed in this new cohort, likely reflecting the relatively lower age range (4-
12 years compared to 5-77 years) given that these features generally emerged in late 
adolescence/adulthood. We specifically evaluated the cohort to assess if a characteristic facial 
gestalt was evident across individuals with pathogenic or likely pathogenic variants across 
our original and this expanded clinical cohort (Supp. Figure S4) (Dudding-Byth, et al., 2017). 
Although a clearly recognizable facial gestalt was not obvious, there are some similarities. 
Children have a wide forehead with variable ptosis, epicanthic folds, down-slanting palpebral 
fissures, wide nasal bridge, long philtrum and pointed chin. Adults have a wide forehead with 
prominent supraorbital fissures with variable horizontal eyebrows, thin nasal bridge and 
down-slanting palpebral fissures. Age progression of the face shows shortening of the 
Page 13 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
13 
 
philtrum with widening of the nasal base. The facial gestalt spectrum associated with THOC2 
pathogenic variants will continue to emerge as more individuals are reported. 
 
The two males with splice variants (individuals 6 and 7) and the monozygotic twins with 
missense variant p.His1187Tyr (individual 3 and 4) inherited the THOC2 variant from their 
mother. As was the case in our original cohort, the heterozygous mothers were unaffected, 
with normal learning and health. All had highly skewed X cell inactivation (XCI) (Table 1). 
In comparison, individual 7, who was a female with a de novo missense variant 
(p.Tyr517Cys) had a particularly severe neurocognitive presentation with infantile onset 
epileptic encephalopathy and profound intellectual disability. At age 10 y she remains non-
ambulant and non-verbal. Unfortunately, we did not have access to her genomic DNA for 
testing the XCI status. We do note that severely affected females with de novo variants in X-
linked genes have been reported by us and others (Palmer, et al., 2016; Snijders Blok, et al., 
2015; Zweier, et al., 2014), and that differences in XCI in blood do not always provide an 
explanation for the range of phenotypic expression in heterozygous females.    
 
A range of protein-protein interactions are required for mRNA export (Chi, et al., 2013). 
Proteins with altered stability (Hirayama, et al., 2008), localization (Beaulieu, et al., 2013) 
(e.g., THOC6 p.Gly46Arg implicated in syndromic ID) or interaction (Chi, et al., 2013) can 
impact mRNA export and consequently disrupt normal cell function. Likewise, THOC2 
variants can cause neuronal defects due to altered protein interactions, stability, localization 
and/or structure, which can impact normal THOC2 functions such as mRNA export or its 
mRNA binding properties. We did not observe mislocalization of the THOC2 variant 
proteins in cultured cells and did not test alterations in their interaction with the other known 
or unknown TREX proteins. However, significantly reduced levels of a number of new 
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(p.Tyr517Cys, p.His1187Tyr, p.Thr696Ile, p.Gly713Asp) and published (p.Leu438Pro, 
p.Ile800Thr (Kumar, et al., 2015)) missense THOC2 variant proteins are due to impaired 
protein stability or reduced levels of normal mRNA due to aberrant splicing in 
exon28:c.3503+4A>C affected individuals (see below). We also noted increased stability of 
p.Asn1261His THOC2 protein. We and others have shown that THOC2 controls TREX 
function by maintaining the stability of THOC1, 3, 5 and 7 subunits (Chi, et al., 2013; 
Kumar, et al., 2015). Reduced levels of THOC2 missense variant proteins are most likely due 
to enhanced proteasome-mediated degradation as THOC2 is ubiquitinated (Lopitz-Otsoa, et 
al., 2012). Published evidence shows that molecular chaperons protect proteins from 
degradation by promoting co rect protein folding and assembly. Reduced stability of a set of 
variant THOC2 proteins may be due to structural changes or impaired protective-association 
with an unknown chaperon, which can be TREX complex subunit or an unrelated protein. 
Indeed, reduced levels of THOC2 protein in a girl with a de novo X;8 translocation creating a 
PTK2-THOC2 gene fusion has also been implicated in non-progressive form of congenital 
ataxia, cognitive impairment and cerebellar hypoplasia (Di Gregorio, et al., 2013). This is 
consistent with observations showing that THOC2 depletion has different consequences in 
different organisms. Some of the examples include reduced levels of Thoc2 leading to 
significant increase in length of neurites in rat primary hippocampal neurons (Di Gregorio, et 
al., 2013) and C. elegans thoc2 knockouts that are completely immobile, slow-growing, 
sterile, have functional defects in specific sensory neurons and die prematurely (Di Gregorio, 
et al., 2013). D. rerio Thoc2 is essential for embryonic development (Amsterdam, et al., 
2004) and in D. melanogaster S2 cells Thoc2 knockdown inhibits mRNA export and cell 
proliferation (Rehwinkel, et al., 2004). THOC2 depletion also results in chromosome 
alignment, mitotic progression and genomic stability in human HeLa cells (Yamazaki, et al., 
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2010). Finally, Thoc2 and Thoc5 knock down experiments have shown their role in 
regulation of embryonic stem cell self-renewal (Wang, et al., 2013).  
 
Compared to his unaffected heterozygous carrier mother, who showed skewed X-
inactivation, the exon35:c.4450-2A>G variant caused defective splicing in the male proband 
resulting with not only a truncated THOC2 protein but also abnormal accumulation in his 
skin fibroblasts. The truncated 1535 amino acid THOC2 protein lacks C-terminal 110 amino 
acids (part of a putative RNA binding domain) of the 1593 normal THOC2 protein but added 
52 amino acids coded from the un-spliced intron (Figure 5; (Pena, et al., 2012)). Interestingly, 
whereas cDNA sequencing of exon 27-30 region for the exon28:c.3503+4A>C THOC2 
variant showed normal splicing in mother and father, the affected son showed aberrant 
splicing resulting in normally spliced (about 2/3
rd
) and intron 28 retained (nearly 1/3
rd
) 
mRNAs. A 143 bp intron 28 retention is predicted to translate a 1175 amino acid THOC2 
protein (1168 normal and 7 amino acids coded by the retained intron 28 fragment) completely 
lacking the C-terminal RNA binding region (Figure 5). Both affected individuals carrying the 
splice-variants presented with severe neurocognitive features, consistent with the phenotype 
of the majority of individuals with missense variants with supportive functional evidence. 
Taken together, exon35:c.4450-2A>G and exon28:c.3503+4A>C THOC2 splice variants 
present interesting biological scenarios; the former resulting in 1535 amino acid truncated 
protein that is present at higher level and the latter with both normal (albeit potentially much 
reduced) and a 1175 amino acid truncated THOC2 protein. We postulate that the clinical 
outcomes in the exon35:c.4450-2A>G individual are caused by partial loss of function due to 
loss of 110 amino acid C-terminal region and accumulation of the truncated THOC2 protein. 
However, pathogenicity in exon28:c.3503+4A>C affected individual is most likely caused by 
reduced levels of normal and potential dominant-negative effects of the C-terminally 
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truncated THOC2 protein. That reduced THOC2 protein levels are associated with ID and 
other clinical symptoms is emerging as a frequent theme; e.g., due to reduced THOC2 protein 
stability caused by missense variants (see above) and now an aberrant splicing event. Indeed 
reduced THOC2 levels are shown to destabilize the TREX complex in humans (Chi, et al., 
2013; Kumar, et al., 2015) and removal of any THO subunit causes destabilization of other 
TREX components in yeast (Pena, et al., 2012). Interestingly, p.Arg1307Trp THOC2 variant 
was recently reported to effect THOC2-THOC1 binding and thus THOC1 degradation in 
MDAMB157 breast cancer cells (Lapek, et al., 2017).   
 
Systematic studies on functional effect of Tho2 C-terminal RNA binding region in yeast 
provide interesting explanation as to how the truncated THOC2 protein can perturb normal 
mRNA export function in human cells (Pena, et al., 2012) (Figure 6). The yeast data show 
that whereas ∆Tho2 strain does not grow at 37ºC (restrictive temperature), Tho2∆1408-1597 and 
Tho∆1271-1597 growth is considerably reduced suggesting that C-terminal 1271-1597 amino 
acids are required for cell survival at restrictive temperature (Pena, et al., 2012). If the 
exon28:c.3503+A>C variant caused complete splicing defect retaining intron 28 in all 
mRNAs, the cells would translate only a 1175 amino acids (with 1168 normal) THOC2 
protein; essentially lacking the C-terminal region encompassing the RBD domain that when 
deleted in yeast strain (Tho∆1271-1597) totally abolishes their growth at 37ºC. However, the 
affected boy carrying a single allele of the exon28:c.3503+A>C THOC2 variant, although 
with severe clinical symptoms, is alive. This could be explained by presence of reduced 
levels of THOC2 protein produced from translation of about 2/3
rd
 normally-spliced mRNA in 
the affected white blood cells. Taken together, clinical outcomes in the affected boy may be 
due to perturbed mRNA export caused by reduced levels of THOC2 protein and perhaps also 
C-terminally truncated non-functional THOC2 protein translated from about 1/3
rd
 aberrantly 
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spliced mRNAs that retain intron 28. It is though likely that the severe effects due to 
truncated and/or reduced THOC2 protein in the affected individuals may be compensated by 
other TREX proteins and may explain the survival of the girl with congenital ataxia, 
cognitive impairment and cerebellar hypoplasia due to a de novo X;8 translocation creating a 
PTK2-THOC2 gene fusion, who expresses reduced levels of the THOC2 protein (Di 
Gregorio, et al., 2013). For example, REF knockdown increases UIF protein levels 
(Hautbergue, et al., 2009) and Nxf1 depletion results in increased levels of THOC2 
(Viphakone, et al., 2012).     
 
We also identified a set of THOC2 missense variants that do not reach ACMG criteria for 
(likely) pathogenicity. This includes four previously unreported variants (p.Arg77Cys; 
p.Ser1108Leu; p.Arg1121Gly and p.Asn1261His) in five affected individuals (including a 
brother pair) which are absent from databases of reference individuals (ExAC/ gnomAD) 
(Lek, et al., 2016), affect highly evolutionarily conserved amino acid residues, and in silico 
analyses are supportive of pathogenicity (Table 1). Consistent with not satisfying the ACMG 
criteria, they remain variants of uncertain clinical significance in the absence of additional 
supportive functional evidence. Specifically, the missense variants in individuals 8-10 and 12 
did not affect protein stability in our cellular assay system. However, the variants may have a 
detrimental effect on THOC2 function due to altered protein structure impacting protein-
RNA and/or protein-protein interactions with known or unknown TREX subunits. 
Indeed amyotrophic lateral sclerosis (ALS)-linked Matrin 3 variant proteins exhibit altered 
interactions with specific TREX proteins and lead to nuclear mRNA export defects of both 
global mRNA and more specifically, the TDP-43 and FUS mRNAs, linking cellular transport 
defects to ALS (Boehringer, et al., 2017). In addition, we note that two of the THOC2 
variants (p.Leu313Phe and p.Ser1012Pro) in our original cohort (Kumar, et al., 2015) 
Page 18 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
segregated with NDDs in multiple individuals in families, but also lacked evidence of a 
detrimental effect on protein stability. Detailed clinical information on the affected 
individuals carrying these VOUS is presented in the supplementary data and summarized in 
Table 2. Similarities in clinical presentation between the majority of affected individuals in 
this group and with those with (likely) pathogenic variants are apparent, including severe-
profound intellectual disability, behavioural difficulties including autistic features, infantile 
hypotonia, seizure disorders, gait abnormalities, neuroradiological features including white 
matter abnormalities and ventricular dilatation, microcephaly and short stature. Individual 8 
had cerebellar vermal hypoplasia which was also noted in an individual from the original 
cohort (Kumar, et al., 2015). Individuals 8 and 11 were considered to share overlapping facial 
features with other members of the cohort (Supp. Figure S4). However, many of these 
features are relatively common in neurodevelopmental disorders in general, and we do not yet 
consider the phenotype of THOC2-related disorder to be distinctive enough to strongly 
weight assessment of pathogenicity of novel variants. The challenge of proving causality for 
previously unreported missense variants in NDD genes is well recognized and speaks to the 
need for ongoing intertwined clinical and research efforts to clarify causality of VOUS 
(Wright, et al., 2018).  
 
THOC2 is ubiquitously expressed in all human tissues (Thul, et al., 2017) and is highly 
expressed in the developing and mature human (Johnson, et al., 2009; Kumar, et al., 2015; 
Uhlen, et al., 2015) and mouse brain, with higher abundance in frontal cortex and cerebellum 
(Di Gregorio, et al., 2013; Kumar, et al., 2015). THOC2 is an essential mRNA export factor 
as its siRNA-mediated depletion results in almost complete retention of mRNAs in the cell 
nucleus (Chi, et al., 2013), potentially toxic to the cell. These data are consistent with the 
findings that THOC2 is a highly-constrained gene (Samocha, et al., 2014) and THOC (e.g. 
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THOC1, 3, 5, 6 and 7) genes are essential for cell survival (Blomen, et al., 2015). Taken 
together, as THOC2 knockout cells will not survive due to complete mRNA nuclear 
retention, we predict that the identified THOC2 variants represent partial loss-of-function that 
disrupt normal mRNA export in neuronal and possibly other cell types, potentially causing 
variable clinical presentations.  
 
TREX complex couples transcription and mRNA biogenesis with nuclear mRNA export and 
has emerged as an essential pathway in embryogenesis, organogenesis and differentiation 
(Heath, et al., 2016). For example, Thoc2 and Thoc5 selectively bind and regulate export of 
mRNAs involved in maintenance of pluripotency (e.g. Nanog, Sox2, Esrrb, and Klf4 
mRNAs) (Wang, et al., 2013) and Thoc5 in hematopoiesis and heat shock (Katahira, et al., 
2009; Mancini, et al., 2010). Lack of Thoc1 and Thoc5 in mice is embryonic lethal (Mancini, 
et al., 2010; Wang, et al., 2006). Mouse modeling shows that both Thoc1 and Thoc5 
knockouts are embryonic lethal (Mancini, et al., 2010; Wang, et al., 2006). However, Thoc1 
and Thoc5 expression in a range of developing and adult tissues may indicate that the two 
genes have more essential role in early embryonic development compared to less stringent 
requirement during later stages of embryonic or adult development (Mancini, et al., 2010; 
Wang, et al., 2006); a functional pattern most likely also true for the THOC2 gene. 
Essentiality of THOC2 gene indicates that THOC2 knockout will also be lethal. However, 
reduced levels or perturbed functionality can lead to a range of NDD phenotypes as observed 
for a cohort of THOC2 variants identified by us. It is now well-established that development 
of brain depends on tightly regulated and complex sequence of events involving neuronal and 
glial cell proliferation, migration and maturation (Chiurazzi and Pirozzi, 2016). Therefore, it 
is not surprising that our THOC2 variant data and published work (Dickinson, et al., 2016) 
provides strong evidence that even subtle alterations to the canonical molecular pathways 
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such as mRNA export, otherwise essential for cellular life, can be tolerated but at a cost of a 
NDD.  
 
In summary, we present detailed clinical data on seven individuals with THOC2-associated 
ID caused by both missense and splice variants that meet ACMG criteria for (likely) 
pathogenicity. They have a core phenotype of ID, and common findings of behavioural 
disorders, infantile hypotonia, gait disturbance and growth impairment, similar to the affected 
males with THOC2-associated ID we previously reported (Kumar, et al., 2015). Other than 
the affected female with a de novo missense variant, heterozygote carrier females are 
typically unaffected. We also present clinical data on five individuals with four previously 
unreported rare missense variants that show clinical overlap with our core group, but where 
convincing evidence for causality is still required. The significance of these variants may be 
clarified as further individuals with THOC2 variants are reported. 
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Figure legends 
FIGURE 1 Location of variant amino acids and structural features in THOC2 protein. 
Ubiquitinated (K139 and K1084 (Kim, et al., 2011) and K345 (Lopitz-Otsoa, et al., 2012; 
Wagner, et al., 2011)), phosphorylated (S1448 and 1486 (Olsen, et al., 2006)) amino acid 
residues, potential RNA binding domain (RBD) and destruction box (D-box) and KEN box 
sequences that interact with the Anaphase Promoting Complex/Cyclosome (APC/C) for 
protein ubiquitination and subsequent destruction by the proteasome (Morgan, 2013) are 
shown. Unreported (orange) and published (black: (Kumar, et al., 2015)) missense variants 
effecting THOC2 protein stability are marked with red lollipops. The positions of two splice 
variants are also shown (red). 
 
FIGURE 2 Front and side facial views of the affected individuals with THOC2 variants. 
 
FIGURE 3 Functional testing of THOC2 missense variants. A: THOC2 variant protein 
stability is reduced in HEK293T cells. pCMV-Myc-THOC2 wild-type or variant expression 
constructs and pEGFP-C1 plasmid (transfection control) were transfected into HEK293T 
cells. Total protein lysates of cells 24hr post-transfection were analysed by western blotting 
with mouse anti-Myc (clone 9E10; Sigma), mouse anti-EGFP (clones 7.1 and 13.1; Roche) 
and rabbit anti-β-tubulin (loading control; Abcam) antibodies. pCMV-Myc-THOC2 
p.Ile800Thr construct expressing the p.Ile800Thr protein shown to have reduced stability was 
used as a control (Kumar, et al., 2015). Western blot signals were quantified using ImageJ 
software. Averages of the Myc-THOC2 proteins normalised to the housekeeping β-tubulin 
signal from two independent runs are shown. B: Myc-Tyr517Cys THOC2 protein half-life is 
significantly reduced in HEK293T cells. pCMV-Myc-THOC2 or pCMV-Myc-THOC2-
Tyr517Cys expression constructs and pEGFP-C1 plasmid (transfection control) were 
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transfected into HEK293T cells. Next day the cells were cultured in the presence of 100 
µg/ml translation inhibitor cycloheximide and cells harvested at the time points shown. Total 
protein lysates were analysed by western blotting with mouse anti-Myc, mouse anti-EGFP 
and rabbit anti-β-tubulin (loading control) antibodies.   
 
FIGURE 4 Exon35:c.4450-2A>G variant abolishes splicing of intron between exons 34-35. 
A: Part of the THOC2 gene showing location of the A/G nucleotide in the heterozygous 
carrier mother and A>G splice variant in the affected son. The C-terminal part of the 1593 
amino acid wild type and 1535 amino acid (that contains 1483 normal and 52 amino acids 
coded by the unspliced intron) THOC2 protein in the affected boy are also shown. B: Gel 
showing a 194 bp RT-PCR product from the normally-spliced mRNA of the heterozygous 
carrier mother and a 537bp product from defective splicing of mRNA causing retention of an 
intron between exon 34-35 in the affected son. RT-PCR products from total RNA isolated 
from passage 3 (lanes 1-2) and 5 (lanes 3-4) fibroblasts. Location of the forward and reverse 
primers within exons 34 and 35 is shown. C: Sanger sequencing chromatograms of PCR 
products amplified from genomic and cDNA of the affected son and his heterozygous carrier 
mother using primers located within exon 34 and 35. Genomic DNA around the Exon34-
Intron-Exon35 region is shown. D: Western blot showing THOC2 protein in the affected son 
and his carrier mother's skin fibroblasts. TREX subunit UAP56 was used as a loading control. 
E: RT-qPCR showing levels of the THOC2 mRNA in the affected son and his carrier 
mother's skin fibroblasts. F: Immunofluorescence detection of THOC2 in skin fibroblasts of 
the unaffected mother and affected son. 
 
FIGURE 5 Exon28:c.3503+4A>C variant causes aberrant splicing of intron 28 A: Part of the 
THOC2 gene showing location of the A/C nucleotide in the heterozygous carrier mother and 
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A>C splice variant in the affected son. The C-terminal part of the 1593 amino acid wild type 
and 1175 amino acid (that contains 1168 normal and 7 amino acids coded by the unspliced 
intron) THOC2 protein in the affected son are also shown. B: Gel showing a 491 bp RT- PCR 
product from the normally-spliced heterozygous carrier mother and unaffected father, and 
491 bp and 634 bp (retaining 143 bp of the 503 bp intron 28) RT-PCR products derived from 
the normally and aberrantly spliced mRNAs, respectively, in the affected son. Location of the 
forward and reverse primers within exons 27 and 30 is shown. C: Sanger sequencing 
chromatograms of PCR products amplified using primers located within exons 27 and 30 
from genomic and cDNA of unaffected father and mother (carrier with 98:2% skewing), and 
the affected son.  
 
FIGURE 6 Summary of truncated human THOC2 proteins translated from aberrantly-spliced 
mRNAs and functional outcomes of yeast C-terminal Tho2 deletion strains (Pena, et al., 
2012). Blue boxes depict the 52 and 7 amino acids coded by unspliced intron sequences of 
exon35:c.4550-2T>C and exon28:c.3503+4A>C variants, respectively. WT, +++ = normal, 
∆1408-1597aa, ++ and ∆1271-1597aa = reduced growth at restrictive temperature. 
 
TABLE 1 Detailed description of the THOC2 variants. 
 
TABLE 2 Summary of clinical data. 
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Supplementary data files 
 
Supplementary file with detailed clinical data 
 
Supplementary Figure S1. THOC2 variant amino acid residues are highly conserved. 
Amino acid sequence alignments show the variant amino acid residue (red) at the conserved 
positions (green). The amino acid sequences were aligned using www.uniprot.org/align/. 
 
Supplementary Figure S2 Brain MRI of the individual carrying the exon28: c.3503+4A>C 
THOC2 variant. Red arrow shows myelination and yellow arrow shows periventricular white 
matter lesion at age 2y 11m.  
 
Supplementary Figure S3 A: THOC2 variant proteins are normally localised in HeLa and 
HEK293T cells. HeLa and HEK293T cells cultured on Poly-L-lysine coated coverslips (BD 
Biosciences) were transfected with wild type or variant Myc-THOC2 expression plasmids 
and detected by immunofluorescence using mouse anti-Myc (9E10; Sigma) primary and 
Donkey anti-rabbit-IgG Alexa 488 secondary antibody (Life Technologies). Only HeLa cell 
localisations at 630× magnification are shown. B: Nuclear and cytoplasmic (HEK293T; 
average 250 cells each) and nuclear and nuclear plus cytoplasmic (HeLa; average 400 cells 
each) staining was visually scored and plotted. Note that nuclear plus cytoplasmic instead of 
only cytoplasmic staining for HeLa was scored because all the cells with cytoplasmic staining 
also had nuclear staining. 
 
Supplementary Figure S4 Children and adolescents/adults within current and previously 
reported THOC2 cohorts. Images connected by vertical grey shading represent the same 
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individual at different ages.  
 
Supplementary Table S1 Primers list (PCR and overlap PCR mutagenesis). 
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TABLE 1 Detailed description of the THOC2 variants. 
    Individual From 
Method of 
identification 
Position NM_001081550 
Mode of 
inheritance 
CADD 
Provean 
score 
Provean 
prediction 
GERP++ Phylop 
gnomAD 
frequency 
Polyphen2* 
Variant 
plasmid 
tested 
Reduced 
Protein 
Stability 
ACMG 
pathogenicity 
classification*
*  
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e
 
 
  
Kumar et al 
2015 AJHG 
X-Chr Exome 
sequencing 
122799566 
c.1313T>C:p.Le
u438Pro 
Maternal 
inheritance 
28.1 -6.08 Deleterious 5.7 1.902 absent D YES YES LP 
1 Australia Trio WES 122767853 
c.2087C>T:p.Th
r696Ile 
De novo 27.4 -5.47 Deleterious 5.03 0.963 absent D YES YES DP 
2 USA WES 122766890 
c.2138G>A:p.Gl
y713Asp 
De novo 31 -4.69 Deleterious 5.73 2.412 absent D YES YES DP 
  
Kumar et al 
2015 AJHG 
X-Chr Exome 
sequencing 
122765621 
c.2399T>C:p.Ile
800Thr 
Maternal 
inheritance 
23.9 -4.01 Deleterious 5.97 2.016 absent P YES YES LP 
3-4 
Canada/German
y/Russia 
Identical twins 
WES  122757079 
c.3559C>T:p.Hi
s1187Tyr 
Maternal 
inheritance; 
Mother 
skewed 
(99.9:0.1%) 
23.1 -5.07 Deleterious 6.07 2.571 absent P YES YES LP 
                  
S
p
l
i
c
e
 
5 Japan Trio WES 122757634 
Exon28:c.3503+
4A>C 
Maternal 
inheritance; 
Mother 
skewed 
98:2% 
10.8 N/A N/A 5.57 1.86 absent N/A N/A ND LP 
6 Canada WES  122747561 
Exon35:c.4450-
2A>G 
Maternal 
inheritance; 
Mother 
skewed 
94:6% 
23.7 N/A N/A 5.25 1.735 absent N/A 
Fibrobla
sts of the 
affected 
male 
proband 
and  
carrier 
mother 
NO LP 
 
               
  
M
i
s
s
e
n
s
e
 
7 
USA Epi4K 
Consortium & 
Epilepsy 
Phenome/Geno
me Project; 
Nature 501:217-
221, 2013 
WES 122778639 
c.1550A>G:p.T
yr517Cys 
De novo 26.6 -7.87 Deleterious 5.84 1.955 absent D YES YES DP 
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8 USA WES 122837349 
c.229 
C>T:p.Arg77Cy
s 
Maternal 
inheritance 
25.8 -3.07 Deleterious 5.09 2.219 absent P YES NO VOUS 
  
Kumar et al 
2015 AJHG 
X-Chr Exome 
sequencing 
122802090 
c.937C>T:p.Leu
313Phe 
Maternal 
inheritance 
23.8 -2.44 Neutral 5.38 2.248 absent D YES NO VOUS 
  
Kumar et al 
2015 AJHG 
X-Chr Exome 
sequencing 
122759786 
c.3034T>C:p.Se
r1012Pro 
Maternal 
inheritance 
23.8 -4.54 Deleterious 5.6 1.87 absent P YES NO VOUS 
9-10 Spain 
WES of two 
affected 
brothers 
122757818 
c.3323C>T:p.Se
r1108Leu 
Variant not 
detected in 
mother's 
peripheral 
blood or 
hair roots so 
likely 
germline 
mosaicism 
15.4 0.96 Neutral 5.91 2.493 absent B YES NO LP or VOUS 
11 Spain 
WES parents 
and affected 
individual 
122757780 
c.3361A>G:p.Ar
g1121Gly 
Maternal 
inheritance 
24.2 -6.49 Deleterious 5.91 0.834 absent D NO NO VOUS 
12 USA WES 122756613 
c.3781A>C:p.As
n1261His 
Maternal 
inheritance; 
testing of 
family 
members 
shows 
likely new 
variant in 
mother 
22.8 -1.81 Neutral 5.34 1.768 absent D YES NO VOUS 
 
*Probably damaging, D; Possibly damaging, P; Benign, B; N/A, not applicable; ND, not determined **De novo Pathogenic, DP; Likely Pathogenic, LP; Variant of unknown Significance, VOUS 
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TABLE 2 Summary of clinical data. 
 (likely) pathogenic    VOUS   
Individual 1 2 3 4  5 6  7  8 9 10 11 12 
Variant details 
c.2087C>T: 
p.Thr696Ile 
c.2138G>A: 
p.Gly713Asp 
c.3559C>T: 
p.His1187Tyr 
Twin 1 
c.3559C>T: 
p.His1187Tyr 
Twin 2 
 
Exon28: 
c.3503+4A>C 
Exon35:c.4450-
2A>G  
c.1550A>G: 
p.Tyr517Cys  
c.229C>T: 
p.Arg77Cys 
c.3323C>T: 
p.Ser1108Leu       
Sib 1 
c.3323C>T: 
p.Ser1108Leu    
Sib 2 
c.3361A>G: 
p.Arg1121Gly 
c.3781A>C: 
p.Asn1261His 
Gender Male Male Male Male 
 
Male Male 
 
Female 
 
Male Male Male Male Male 
Age (years) 12 5 7 7 
 
3 10 
 
10 
 
9 17 12 44 6 
Perinatal 
features                
Gestation 
(weeks) 
36 37 37 37 
 
37 41 
 
NA 
 
41 40 37 Premature Term 
Low birth 
weight (<2.5kg) 
Yes No Yes Yes 
 
No No 
 
NA 
 
No No No No No 
Birth weight (g) 2000 2650 1990 2420 
 
3018 4365 
 
NA 
 
3770 2880 3480 NA 5200 
Neurologic 
features                
Intellectual 
disability 
Severe Mod+ Mod+ Mod+ 
 
Severe Severe 
 
Profound 
 
Profound Severe Severe Severe Mod+ 
Speech delay 
Yes, single 
words, 
signs 
Yes, non-verbal Yes Yes 
 
Yes, non-
verbal 
Yes, nasal 
dysarthria  
Yes, non- 
verbal  
Yes, non-verbal Yes Yes Yes, severe 
Yes, 2-3 word 
phrases 
Hypotonia No Yes NA NA 
 
Yes 
Yes, central 
hypotonia 
appendicular 
spasticity 
 
Yes 
 
Yes, central 
hypotonia, 
appendicular  
spasticity 
No No Yes 
Yes, central 
hypotonia, 
appendicular 
spasticity 
Hyperkinesia No No Yes Yes 
 
Yes No 
 
No 
 
No No Yes No No 
Tremor No 
Yes, 
intermittent 
No No 
 
No Yes 
 
No 
 
No No No No No 
Epilepsy No Suspected No No 
 
No No 
 
Yes, epileptic 
encephalopathy  
Yes, infantile 
spasms 
No No No 
Yes, 
Lennox-Gestaut 
Gait 
disturbances 
No 
Yes, 
gait/balance 
problems 
Yes, toe 
walking 
Yes,  toe 
walking  
Non 
ambulatory 
Yes, 
ataxia/broad 
based gait, 
spasticity 
 
Non 
ambulatory  
Non ambulatory 
Yes,  'clumsy' 
and toe 
walking 
Yes, 'clumsy' 
and toe 
walking 
Non 
ambulatory 
Yes, 
spastic 
quadiplegia 
Behaviour 
problems 
No Yes Yes Yes 
 
Yes, ASD No 
 
NR 
 
No Yes, ASD Yes, ASD Yes 
Yes, 
short attention 
span 
Anxiety No No No No 
 
No No 
 
NR 
 
No Yes Yes No No 
Depression No No No No 
 
No No 
 
NR 
 
No No No No No 
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Brain MRI/CT 
MRI 
normal 
Thin corpus 
callosum, 
dysgyria 
ND ND 
 
Ventricular 
dilatation, 
delayed 
myelination, 
peri-
ventricular 
white matter 
abnormality 
Slight 
prominence of 
cerebrofluid 
spaces. 
 
MRI normal 
 
Cerebellar 
vermal 
hypoplasia, thin 
corpus 
callosum, 
dilated 
ventricles 
ND ND ND 
Unilateral 
Periventricular 
leucomalacia 
Growth 
parameters                
Microcephaly 
(≤3%) 
Yes Yes,< 1% No No 
 
No Yes,2% 
 
No, 5% 
 
No No NA Yes No 
Short stature 
(≤3%) 
Yes Yes No No 
 
No No 
 
No 
 
No Yes (<1%) No Yes (<1%) Yes, (<1%) 
Overweight 
(BMI≥25) 
No No No No 
 
No No 
 
No 
 
No No No Yes (39.9) No (4%) 
Broad high 
forehead 
Yes Yes Yes Yes 
 
No No 
 
NR 
 
No Yes Yes Yes No 
Other features 
 
Mild joint 
laxity, subluxed 
hips, disordered 
sleep,  feeding 
difficulties (g-
tube 
dependency), 
laryngomalacia, 
micrognathia, 
abnormal 
palmar creases 
Noonan 
facies, pes 
planus, 
hypospadias 
Noonan 
facies, pes 
planus, 
hypospadias 
  
Clinodactyly, 
nystagmus, 
abnormality 
soft palate, 
hypoteloric, 
nystagmus 
 
Cortical visual 
impairment  
Cryptorchidism, 
astigmatism, 
myopia, 
strabismus. 
Tracheostomy 
and 
gastrostomy 
dependent: 
chronic 
respiratory 
failure, 
sialorrhea, 
dysphagia, 
esophageal 
reflux. Type I 
diabetes. 
Pes cavus, 
nocturnal 
eneuresis 
 
Osteoarthritis, 
glaucoma, 
cataracts, 
supraventricular 
tachycardia, 
cardiomegaly, 
micropenis 
Cryptorchidism, 
hyperopia, 
astigmatism, 
right optic nerve 
coloboma. 
Postnatal NICU 
admission with 
feeding issues. 
 
Abbreviations: %: centile; ASD: autism spectrum disorder; CT computerised tomography scan; g-tube: gastrostomy tube; mod+: at least moderate severity; MRI: magnetic resonance imaging; ND: not done;  NA: not 
available; NR: not reported; NICU: neonatal intensive care unit; VOUS: variant of uncertain significance 
Page 36 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
194x70mm (300 x 300 DPI)  
 
 
Page 37 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
215x402mm (300 x 300 DPI)  
 
 
Page 38 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
106x156mm (300 x 300 DPI)  
 
 
Page 39 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
223x124mm (300 x 300 DPI)  
 
 
Page 40 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
134x148mm (300 x 300 DPI)  
 
 
Page 41 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
156x99mm (300 x 300 DPI)  
 
 
Page 42 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
231x127mm (300 x 300 DPI)  
 
 
Page 43 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
139x169mm (300 x 300 DPI)  
 
 
Page 44 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
236x140mm (300 x 300 DPI)  
 
 
Page 45 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
1 
 
SUPPLEMENTARY DATA FILE 
 
 
Severe neurocognitive and growth disorders due to variation in THOC2, an essential 
component of nuclear mRNA export machinery 
 
 
Raman Kumar
1
, Alison Gardner
1
, Claire Homan
1
, Evelyn Douglas
2
, Heather Mefford
3
, 
Dagmar Wieczorek
4
, Hermann-Josef Lüdecke
4
, Zornitza Stark
5
, Simon Sadedin
6
, The Broad 
CMG
7
, Catherine Bearce Nowak
8
, Jessica Douglas
8
, Gretchen Parsons
9
, Paul Mark
9
, Lourdes 
Loidi
10
, Gail Herman
11
, Theresa Mihalic Mosher
11
, Meredith K Gillespie
12
,  Lauren Brady
13
, 
Mark Tarnopolsky
13
, Irene Madrigal
14
, Jesús Eiris
15
, Laura Domenech Salgado
16
, Raquel 
Rabionet
16
, Tim M Strom
17
, Naoko Ishihara
18
, Hidehito Inagaki
19
, Hiroki Kurahashi
19
, 
Tracy Dudding-Byth
20,21
, Elizabeth Palmer
20,22
, Michael Field
20
, Jozef Gecz
1,23* 
 
 
1
Adelaide Medical School and the Robinson Research Institute, The University of Adelaide, 
Adelaide, SA5000, Australia; 
2
Genetics and Molecular Pathology, SA Pathology, Adelaide, 
SA5000, Australia; 
3
Division of Genetic Medicine, Department of Pediatrics, University of 
Washington & Seattle Children’s Hospital, Seattle, Washington, USA; 4Heinrich-Heine-
University, Medical Faculty, Institute of Human Genetics, Düsseldorf, Germany and Institut 
für Humangenetik, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, 
Germany; 
5
Murdoch Children's Research Institute and  
Department of Pediatrics, University of Melbourne, Melbourne, Australia; 
6
Murdoch 
Children's Research Institute and  
Program in Medical and Population Genetics, Broad Institute of MIT and 
Harvard, Cambridge, Massachusetts, USA; 
7Broad’s Center for Mendelian Genomics, 
Cambridge, Massachusetts, USA; 
8
Boston Children's Hospital, Longwood Avenue, Boston, 
MA, USA; 
9
Spectrum Health Medical Genetics, Grand Rapids, MI, USA; 
10
Fundación 
Pública Galega de Medicina Xenómica, Hospital Clínico Universitario de Santiago de, 
Compostela. Santiago de Compostela, Spain; 
11Nationwide Children’s Hospital and The Ohio 
State University, Columbus, OH, USA; 
12
Children's Hospital of Eastern Ontario Research 
Institute, University of Ottawa, Ottawa, Canada; 
13
Department of Pediatrics, McMaster 
University Medical Centre, Hamilton, Canada; 
14
Fundación Pública Galega de Medicina 
Xenómica, Hospital Clínico Universitario de Santiago de Compostela, Santiago de 
Compostela, Spain; 
15
Unidad de Neurología Pediátrica, Departamento de Pediatría, Hospital 
Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; 
16
Centre 
for Genomic Regulation (CRG), Universitat Pompeu Fabra and CIBERESP, Barcelona 
Institute for Science and Technology, Barcelona, Spain; 
17
Institut für Humangenetik, 
Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Germany;  
18
Department of 
Pediatrics, Fujita Health University School of Medicine, Japan; 
19
Division of Molecular 
Genetics, Institute for Comprehensive Medical Science, Fujita Health University, Japan; 
20
Genetics of Learning Disability Service, Hunter Genetics, Waratah, NSW 2298, Australia; 
21
University
 
of Newcastle, Australia Grow-Up-Well Priority Research Center; 
22
School of 
Women’s and Children’s Health, University of New South Wales, Randwick, NSW 2031, 
Australia; 
23
Healthy Mothers, Babies and Children, South Australian Health and Medical 
Research Institute, Adelaide, SA 5000, Australia. 
 
*Correspondence: Jozef Gecz, 
1
School of Medicine, The Robinson Research Institute, The 
University of Adelaide, North Adelaide, SA5005, Australia. E-mail: 
jozef.gecz@adelaide.edu.au 
Detailed clinical data 
 
 
Page 46 of 67
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
High confidence in pathogenicity of THOC2 variants, ACMG classification likely pathogenic or 
pathogenic.  
 
 
Individual 1: affected male with de novo p.Thr696Ile variant 
This is a 12 year old male, the second child of healthy unrelated Caucasian parent.  He was delivered 
at 36 weeks gestation with a birth weight of 2000g (10th centile), length 42cm (<1
st
 centile) and head 
circumference of 32cm (10-25th centile). He had speech and global developmental delay in infancy, 
but was not noted to have low tone. Aged 12 he has a severe intellectual disability. He has limited 
communication with some signs and a few single words. He was able to walk at 4 years of age. He 
has no history of epileptic seizures. 
  
On examination he has subtle dysmorphic features including a broad high forehead, microcephaly 
(HC 50cm, 2nd centile), and short stature with a height of 111cm (<<1st centile) recorded at 10 years. 
 
Brain MRI was reported as normal. Previous non diagnostic investigations include SNP chromosomal 
microarray and fragile X syndrome testing. 
 
 
Individual 2: affected male with maternally inherited p.Gly713Asp variant  
This is a 5 year old male, the first child of healthy parents. He has a maternal half-brother with a 
diagnosis of attention deficit hyperactivity disorder (ADHD) and a paternal half sister with diagnoses 
of bipolar disorder and ADHD. P enatal history was complicated by maternal hyperemesis throughout 
pregnancy. He was delivered at near term (37+6 weeks), breech by emergency caesarian-section due 
to prolonged rupture of membranes with a birth weight of 2650gm (10
th
 centile), length 47cm (3-10
th
 
percentile) and head circumference 34cm (25-50
th
 percentile).  
 
In the newborn period he was noted to have respiratory distress with biphasic stridor, mild 
laryngomalacia and micrognathia, as well as feeding difficulties. He has disordered sleep and failure 
to thrive, requiring gastrostomy tube feeding. He also has lax joints with a history of subluxing hips.  
He required myringotomy tubes and adenoidectomy. He has difficulty with sleep and requires 
clonidine to fall asleep and stay asleep.   
 
Additional features include the presence of tremor and gait/balance problems. He has had 3 seizure-
like episodes. He had hypotonia, speech and global developmental delay and has likely a moderate 
intellectual disability per his developmental assessments from neurology, and aged 5 years remains 
non-verbal. He has some vocalizations and is adept with a communication device. There are no 
features of autism. There are behavioral problems including occasional aggression thought to be 
related to frustration due to limited communication abilities. He has a history of hand flapping 
behaviors that have now resolved.   
 
On examination he is small in all growth parameters with head circumference most significantly 
affected: he is microcephalic with a head circumference of -3.79 SD. A review of his past head 
circumference measurements show that he has consistently -3 SDs or more since birth to the present.   
He has a broad, high forehead and flatness of the occiput. He has prominent ears with rolled helices.  
He has a flat facial profile.  Palpebral fissures are straight and short. He has mild median epicanthal 
folds. There is a broad nasal root with an upturned tip and a smooth philtrum with a thin upper 
vermillion border and prominent chin. He has small teeth. He has bilateral upper transverse palmar 
creases with normal lower palmar creases and an accessory flexion crease on each 5
th
 finger with mild 
clinodactyly bilaterally. There is a flat hemangioma at the nape of the neck.  
 
On Brain MRI he is noted to have a foreshortened and thin corpus callosum and low brainstem 
volume. No basal ganglia fusion. There is dysgyria with variability in gyral morphology, changes in 
orientation and gyral frequency. The gyral pattern appears finely nodular/polymicrogyria-like in the 
inferior frontal lobes. There are also scattered areas of T2 and FLAIR signal.  
 
Prior non diagnostic investigations include a normal karyotype, normal microarray and a negative 
Prader-Willi methylation study. EEG was normal. 
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Individuals 3 and 4: affected monozygotic twins with maternally inherited p.His1187Tyr 
variants 
These are two 7 1/2 year old monozygotic twin brothers, born to healthy unrelated Russian parents 
after assisted reproduction for unexplained subfertility. The twins were delivered at 37 weeks 
gestation.  Twin one had a birth weight of 1900g (<3
rd
 centile) and length of 46 cm (3
rd
 centile)  and 
twin two a birth weight of 2420g  (10
th
 centile) with length of 48 cm (25
th
 centile)  
 
Delays in their motor development were noted in the first year of life: they were only able to sit 
without support at 12 months of age. Twin 1 walked independently at 1 year 9 months, and twin 1 at 2 
years of age. They have a tendency to toe walk. Expressive and receptive language has been 
significantly delayed and at 7 ½ years of age they have no verbal communication and only limited 
receptive language. They are described as hyperactive and can have some behavioral difficulties 
including auto-aggressive behaviors. They have difficulties coordinating the biting and chewing of 
their food. Both boys had hypospadias.  
 
On examination twin one (aged 5 yr) was 106cm tall (25-50
th
 centile) with a weight of 16.3kg (25-50
th
 
centile) and a head circumference of 40.5cm (10-25
th
 centile). Twin two (aged 5 yr) was 107cm tall 
(25-50
th
 centile) with a head circumference of 51cm (10-25
th
 centile).  Both boys were noted to have a 
flat midface, hypertelorism a short nose, short ears and prominent upper lip.  A differential diagnosis 
of Noonan syndrome had been considered. 
 
Prior non diagnostic investigations included a normal karyotype, normal chromosomal microarray 
(twin two), normal fragile X PCR.  Testing of their mother indicated that she was almost completely 
skewed for X inactivation (0.013:0.987). 
 
 
Individual 5: Affected male with maternally inherited c.3503+4A>C variant 
This is a three year old male. He was delivered at 37 weeks with a birth weight of 3.018kg (25
th
 
centile).  He was noted to have infantile hypotonia. Aged 3 he has been diagnosed with a severe 
intellectual disability. He is non-verbal and has a diagnosis of autism spectrum disorder with some 
challenging behaviors including a tendency to self-injure.  His non-ambulant, but can crawl.  He has 
no history of seizures.   
 
On examination he is noted to have a flat nasal bridge and a down-turned mouth. He has no tremor. 
He is noted to be hyperkinetic. Aged 3 years 10 months his height was 94.5cm (-1.2SD), weight 
13.8kg (-1.0SD) and head circumference was 49cm (-0.8SD) 
 
MRI brain at age 2 years 11 months demonstrates mild dilatation of the lateral ventricles, especially in 
frontal lobes, mildly delayed myelination and an abnormal white matter lesion in the periventricular 
area close to the anterior horn. 
 
Previous normal genetic investigations include a 46, XY karyotype. Copy number analysis was 
performed on the data from exome studies and was non-diagnostic.  
  
  
Individual 6: Affected male with maternally inherited c.4450-2A>G variant.  
This is a 10 year old male born to non-consanguineous parents with a negative family history at 41 
weeks gestation after a pregnancy complicated by first trimester bleeding and maternal hypertension. 
He required oxygen at birth secondary to a small unilateral pneumothorax which resolved 
spontaneously. Birth weight was 9lb 10 oz (>90
th
 centile).  
 
He had infantile hypotonia and was diagnosed with a severe learning disability. He is in a special 
class at school and requires an Individualized Education Plan (IEP). He is able to communicate 
verbally though his speech is affected by an abnormality of the soft palate and nasal dysarthria. 
Additional neurological features including rest and intention tremor, an ataxic broad based gait, 
spasticity, and nystagmus. There are no concerns with his behavior.  
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On examination his head circumference (aged 5 years) was 49 cm (2
nd
 percentile) with a height (aged 
10yr) of 142.1 cm (50-85
th
 centile) and BMI of 17.6kg (50-80
th
 percentile).   He is measurably 
hypoteloric with an intercanthal distance of 2.5 cm (-1SD) and an inter-pupillary distance of 4.5 cm 
(35
th
 percentile). He is noted to have a startle response. He has a thin eyebrows and a slightly flattened 
nasal bridge. He has large ears (>2 SD). His palate is very high and narrow.  He has slight 
clinodactyly of the fingers. He has flat toenails that are slightly depressed at the cuticle. Brain MRI 
shows slight prominence of the cerebro-fluid filled spaces. 
 
Previous genetic investigations including Fragile-X, microarray, and mitochondrial DNA sequencing 
were all negative, though he was found to have borderline complex 1+3 and 4 deficiencies. His 
mother who carries the c.4450-2A>G splice variant has skewed X inactivation (94:6).   
 
Individual 7: affected female with de novo  p.Tyr517Cys variant.  
This is a 10 year old female, the first child of healthy parents, she has an unaffected younger sister. 
She has an infantile onset epileptic encephalopathy. Epileptic seizures were diagnosed at 2 ½ months 
of age: with first seizures consisting of eyelid twitching, followed by clonic activity of the left arm 
and leg. This was treated by phenobarbitone with reasonable seizure control for one month. 
Subsequently clusters of epileptic spasms were diagnosed and EEG demonstrated hypsarrhythmia 
with independent left and right epileptiform activity. Trialled medication included ACTH, vigabatrin 
and clonazepam.  She still has breakthrough seizures. 
 
She was noted to have generalised hypotonia, poor head control and inability to visually fix and 
follow. She has a severe intellectual disability and attends special education schooling with speech 
therapy, physiotherapy and occupational therapy. She is non-verbal and non –ambulatory. She uses a 
gait trainer. She has cortical visual impairment.  
 
At one year of age on examination she was noted to have a head circumference on the 5th centile, 
with height on the 90th centile and weight on the 25th centile.  
 
Prior non-diagnostic testing included a karyotype, subtelomeric FISH, FISH at the Angelman locus, 
sequencing of MECP2 and UBE3A and metabolic screening.  Brain CT and MRI were reported as 
normal.  
 
 
Rare THOC2 variants without supportive functional data and conflicting in silico predictors: 
variants of uncertain clinical significance on ACMG classification  
 
Individual 8: affected male with maternally inherited p.Arg77Cys variant 
This 9 year old male is one of two affected males to a non-consanguineous Caucasian couple. He had 
a younger brother who died at the age of 4 and had a similar clinical presentation with intellectual 
disability, seizure disorder and tracheostomy dependency. His mother also has two unaffected 
daughters by different partners. The mother has a history of early developmental delay but was able to 
complete high school. She also has bipolar disorder and a speech disorder (stutter).  There is an 
extended maternal family history which could be consistent with X linked inheritance. The proband 
has a maternal uncle who died before the age of 4 years, who had microcephaly, a severe progressive 
neurological condition, never being able to walk or talk, and required gastrostomy and tracheostomy. 
The proband’s mother’s maternal aunt also had a son who died between the ages of 2 and 4 with, by 
report, a similar presentation.  The mother’s sister has learning difficulties as school, bipolar disorder 
and a speech disorder (stutter).  The maternal grandmother completed high school and some tertiary 
level eductation.  
 
The proband was born at 41 weeks gestation by spontaneous vaginal delivery, with Apgar scores of 8 
at 1 and 9 at 5 minutes, and minimal resuscitation (transient oxygen) required at birth. Routine 
antenatal ultrasounds were reported as normal, his mother was treated with lamotrigine through the 
pregnancy but there were no other teratogenic exposures. Birth weight was 55.2cm, weight 3.7kg and 
head circumference 33cm. He was noted to have increased muscle tone and poor suck, and was 
transferred to the special care nursery requiring nasogastic feeds. A head ultrasound scan was 
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suggestive of Dandy Walker malformation and he was transferred to a tertiary hospital for ongoing 
care. 
 
The proband has a profound intellectual disability, hypotonic quadriplegic cerebral palsy (GMFCS 
level 5) and intractable infantile onset seizure disorder. He has a history of central apnea and chronic 
respiratory failure and has been dependent on a tracheostomy and ventilator support since the age of 3 
years. He has severe dysphagia and esophageal reflux and has been dependent on gastrostomy feeding 
since the first year of life, initially being able to take some thickened oral feeds. He has sialorrhea and 
previously had parotid duct ligation and salivary gland excision.  He is profoundly delayed and does 
not make eye contact and smiles occasionally in a non-purposeful manner.  He has limited vision, 
strabismus, myopia, astigmatism. He is non-verbal. He is centrally hypotonic with random non-
coordinated movements of the limbs and face, and has developed tongue fasciculations. He previously 
was able to sit and roll, but has now lost those skills.  With age he has increasing peripheral spasticity 
and bilateral ankle clonus. He has no tremor.  
 
 
He has an intractable seizure disorder, which first presented as infantile spasms. His current 
antiepileptic medication is levetiracetam (Keppra) and diazepam (Valium). He also has non epileptic 
myoclonus and muscular spasms which are treated with a muscular relaxant. EEG recordings have 
been abnormal including moderate generalized background slowing and occasional bi-central spike 
and waves.  
 
He has abnormalities on neuroimaging including hypoplasia of the cerebellar vermis, cerebral 
aqueduct stenosis, stable enlargement of the ventricular system reflecting diffuse white matter loss 
and thin corpus callosum, as well as hypoplasia of the brainstem, pons and medulla. 
 
Other medical issues include type I diabetes and left cryptorchidism (requiring orchidoplexy). He has 
a structurally normal heart and kidneys.  
 
On recent examination aged 9 he has a weight of 29.3kg (50
th
 centile), height of 1.132m (25
th
 centile), 
and is noted to be normocephalic.  He has bitemporal narrowing, large ears, a flat nasal bridge, a 
tented mouth, bilateral ptosis and right sided strabismus. He has tapered fingers with puffy feet and 
toes.  
 
Prior non diagnostic investigations include a chromosomal microarray, creatine kinase of 408 u/L at 
birth and 123 u/L aged 2 years, no mutation identified on sanger sequencing of the PLP1 gene.  
 
Individuals 9 and 10: two brothers with maternally inherited p. Ser1108Leu variants.    
These are two brothers born to healthy unrelated Spanish parents, with no additional family history of 
intellectual disability.  
 
The first brother (individual 9) is currently 17 years of age and has diagnoses on the autistic spectrum 
and severe intellectual disability. He was born after an uncomplicated pregnancy at 40 weeks 
gestation. His birth weight was 2880g (10
th
 centile). Apgar scores were 10 at 1 and 5 minutes.  He 
started to walk at 16 months without prior crawling. He had a tendency to toe walk. He is described as 
‘clumsy’. Development of his pincer grasp was delayed, and he was delayed in being able to chew, 
and eat and drink independently. His ability to point to objects and his receptive and expressive 
language development was delayed. He is able to maintain a simple conversation, solve simple 
puzzles, and identify different parts of the body. He can recognize a few logos. He can get easily 
frustrated and has some fears. He has no stereotypical movements. He can initiate simple social 
interactions but does not have symbolic play. He gets anxious prior to novel situations. Eye contact is 
limited.  
 
He has no tremor or seizures. His sleep pattern is normal.   He had nocturnal enuresis until the age of 
12.  
 
There have been significant concerns with short stature, and he was referred to an endocrinologist.  
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On examination he was noted to have a broad forehead and a narrow nasal root with a bulbous tip to 
his nose, thick lips and a short philtrum.  His ears were normally sited. He had a clumsy gait and 
shortening of the Achilles tendon.  His head circumference was 55 cm (50
th
 centile), height 153 cm 
(<<1
st
 centile) and weight 56kg (3-10
th
 centile).  
 
The second brother (individual 10) is 12 years of age and born at 37 weeks after an uncomplicated 
pregnancy. He also has diagnoses of autism and severe intellectual disability, and attends a special 
school.   His birth weight was 3480g (50
th
 centile) and Apgar scores were 9 at 1 and 10 and 5 minutes.  
 
There were no significant concerns with his motor development in the first year of life, but he was 
slow to walk, with this beginning at 18 months. He had a tendency to toe walk. He had significantly 
delayed expressive and receptive speech delay, and no social pointing until 3 years of age. He has no 
expressive language, and very delayed receptive language.  His social development has been delayed 
and he tended to use adults to obtain objects that he wanted. His eye contact has been limited. He can 
engage in simple social interactions with adults but cannot sustain peer relationships. He is described 
as being restless and has a tendency to ‘explosive’ reactions, and can have challenging behaviors 
including mild auto and hetero-aggressive acts when frustrated. He has difficulties adapting to 
changes in his routine and finds it very difficult to sit still. He has stereotypical movements including 
raising up his arms, and clutching and shaking his hands when excited. He is described as clumsy. He 
requires assistance in his activities of daily living.  
 
On examination he is noted to have a broad forehead and widened nasal tip. He has a tendency to toe 
walk, and has shortening of the Achilles tendon. At the age of 12 years 9 months he was 146cm tall 
(10
th
 centile), and weighed 36kg (10
th
 centile). 
 
Prior non-diagnostic investigations include a normal chromosomal microarray (qChip Post) 
 
 
Individual 11: male with maternally inherited p.Arg1121Gly variant 
This male individual died aged 44, and was of Spanish heritage. He was not born prematurely and he 
did not have a low birth weight. He is reported to have been affected by severe intellectual disability, 
with a history of severe speech delay and infantile hypotonia. He received a diagnosis of cerebral 
palsy.  He was reported to be non-ambulant. He had aggressive behavior with self-harm including 
hand-biting and face hitting.  He lived in an institution for individuals with intellectual disability.  He 
had severe speech and language disorder, with around 10 words. Other health issues included asthma, 
osteoarthritis, glaucoma, cataracts, supraventricular tachycardia and cardiomegaly. 
 
He was reported to be microcephalic with short stature, height of 134cm (<<1
ST
 centile), and weight 
(aged 44 years) was 69.8kg (50
th
 centile).  He had a raised BMI (39.9) and subtle dysmorphic features 
including a broad high forehead.  He was reported to have micropenis.    
 
 
Individual 12: male with maternally inherited p.Asn1261His variant 
This male individual is the first child to a 26 year old female. He is currently 5 years 9 month of age. 
The pregnancy was uncomplicated with appropriate prenatal care. There were no known exposures, 
maternal illnesses or medications used during the pregnancy. Routine prenatal testing was normal, and 
there was no gestational diabetes. No prenatal ultrasound or genetic testing was performed. Delivery 
was performed at 42 weeks at home with a midwife and was spontaneous vaginal with vacuum 
extraction due to large size. Birth weight was 5.2 kg, length 57cm, head circumference 38.5cm.  
According to the parents, the baby was initially “blue but his color came right back.” Formal Apgar 
scores were not recorded. He had some irregular breathing at 4 hours of age and was admitted to a 
regional neonatal intensive care unit where he remained for 10 days, mostly for feeding difficulties.   
 
The parents are both healthy and unrelated. They have a daughter, who does not carry the THOC2 
variant, who was admitted to hospital at 8 months of age with a cluster of unresponsive tonic 
episodes. MRA/MVA showed cortical venous thrombi with superior sagittal sinus thrombosis. The 
tonic episodes were treated with Keppra, but she was weaned off this after a normal EEG. She has 
made a good recovery and had normal development.  
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The THOC2 variant is maternally inherited and not present in the maternal grandmother. The 
maternal grandfather is deceased, and no DNA was available for testing. There is no extended family 
history of intellectual disability. The mother has 6 healthy adult full-brothers with normal 
development.   
 
The patient had delayed early milestones, sitting at 11 months and walking at 2 years 11 months. His 
first words were at 12 months of age but he did not gain additional words until he was over 2 years if 
age.  He developed overt seizures between 18-24 months, although subtle and or absence seizures 
may have been present earlier. The seizures were treated with multiple medications but progressed to 
refractory seizures consistent with Lennox-Gastaut syndrome. Initial EEG was consistent with a 
diffuse encephalopathy, follow-up EEG was indicative of numerous brief atonic seizures in the setting 
of a slow background. Seizure frequency and severity have partially responded to oral cannabis which 
was begun as part of a clinical trial at age 5 years 2 months. Prominent seizure type remains as 
infrequent atonic seizures. His development has progressed with improved seizure control. He knows 
more than 100 words and has several two to three word phrases. He can eat with a spoon, help dress 
himself and ride a tricycle. He attends a regular preschool class and receives occupational, physio and 
speech therapies. He has a short attention span.  
 
He has central hypotonia with appendicular spasticity and has received a diagnosis of spastic 
quadriplegia. He is noted to have visual difficulties with hyperopia with astigmatism and a possible 
right optic nerve coloboma. He has had bilateral orchidoplexy for cryptorchidism.  
 
Aged 6 years 10 months, his weight was 17.9kg (3rd centile), height 108.4 cm (<1
st
 centile) and head 
circumference at 5 years 10 months was 50 cm (29 centile). He has mild dysmorphic features, 
including somewhat long facies and prominent ears.  
 
Previous non-diagnostic testing include chromosomal microarray, testing for Fragile X, urinary 
organic acids, serum amino acids, acylcarnitine profile and transferrin isoforms for carbohydrate 
deficient glycoprotein disorders. MRI scan performed at 2 was consistent with mild left sided 
periventricular leukomalacia or delayed myelination. Hearing screening has been normal. Clinical 
exome sequencing was performed on the proband and his parents at Baylor-Miraca, Houston, TX. 
 
 
 
 
Methods used for identifying the THOC2 variants 
p.Thr696Ile (Individual 1) 
Trio whole exome sequencing (WES) and data processing were performed by Genomics 
Platform at the Broad Institute of Harvard and MIT (Broad Institute, Cambridge, MA, USA). 
WES was performed using Illumina exome capture (38 Mb target) and the data was 
processed through a pipeline based on Picard. Single Nucleotide Polymorphism (SNPs) and 
insertions/deletions (indels) were jointly called across all samples using Genome Analysis 
Toolkit (GATK) HaplotypeCaller package version 3.4. 
 
p.Gly713Asp (Individual 2) 
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THOC2 variant was identified using the published method (Tanaka, et al., 2015). 
 
p.His1187Tyr (Individual 3-4) 
Genomic DNA was extracted from peripheral blood samples of the affected individuals and 
their parents using DNA standard extraction kits. Exomes were enriched in solution and 
indexed with version 5 of the SureSelect XT Human All Exon 50Mb kit (Agilent 
Technologies). Sequencing was performed as 101 bp paired-end reads on HiSeq2000/2500 
systems (Illumina). For one of the twins and his parents, 9.4, 8.7 and 12 Gigabases of 
sequence were generated, respectively, resulting in an average depth of coverage of 113, 110 
and 150, with 96.5%, 96% and 97.5% of the target regions covered at least 20 times. Image 
analysis and base calling was performed using Illumina Real Time Analysis. Reads were 
aligned against the human assembly hg19 (GRCh37) using BWA v 0.5.9. Variant calling was 
performed specifically for the regions targeted by the exome enrichment kit using SAMtools 
(v 0.1.18), PINDEL (v 0.2.4t), ExomeDepth (v 1.0.0) and custom scripts. Variant quality was 
determined using the SAMtools varFilter script with default parameters except for the 
maximum read depth (-D) and the minimum P-value for base quality bias (-2), which were 
set to 9999 and 1e-400, respectively. In addition, a custom script was applied to mark all 
variants with adjacent bases of low median base quality. All variants were then annotated 
using custom Perl scripts. Annotation included known transcripts (UCSC Known Genes and 
RefSeq genes), known variants (dbSNP v 135), type of mutation and - if applicable - amino 
acid changes. The annotated variants were integrated into an in-house database. Because the 
index case has a likewise affected twin brother, and the mother displayed an almost 
completely skewed X-inactivation, the database was queried to show homozygosity, 
compound heterozygosity or 'hemizygosity' for X-linked variants. To reduce false positives, 
variants that were already present in the database, or had a variant quality of less than 30, or 
did not pass the filter scripts were filtered out. The raw read data of the remaining variants 
using the Integrative Genomics Viewer (IGV) was manually checked. 
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Exon35:c.4450-2A>G (Individual 5) 
THOC2 variant was identified using the published method (Nishimura, et al., 2014).  
 
Exon28:c.3503+4A>C (Individual 6) 
XHMM software on exome sequencing data, was used to analyse for copy number variation. 
Fifty nanograms of whole blood DNAs from the proband and his parents were used to 
generate a whole exome library using SureSelect QXT Reagent and SureSelect Clinical 
Research Exome (Agilent technologies, Santa Clara, CA). Sequencing was carried out using 
HiSeq 1500 (Illumina, San Diego, CA). After demultiplexing from other sample data, the 
reads were mapped onto the human reference hg19 using BWA 0.7.15 (Li and Durbin, 2009). 
Sorting and recalibration of the mapped reads were done using Picard tools 2.7.1 
(http://broadinstitute.github.io/picard), and variants were called into a VCF file using GATK 
3.6 (Van der Auwera, et al., 2013). Annotations were added using SnpEff and SnpSift 
(Cingolani, et al., 2012). Low quality data and common SNPs of more than 1% frequency in 
Japanese or global populations were filtered out by using dbSNP 147, HGVD
 
(Higasa, et al., 
2016), iJGVD (Nagasaki, et al., 2015) and ExAC
 
(Lek, et al., 2016) data. 
 
p. Tyr517Cys (Individual 7) 
THOC2 variant was identified using the published method (Epi, et al., 2013) 
 
p.Arg77Cys (Individual 8) 
THOC2 variant was identified using the published method (Farwell, et al., 2015). 
 
p.Ser1108Leu and p.Arg1121Gly (Individual 9-10 and 11) 
Both patients had prior investigation with the chromosomal microarray (qChip Post). Carriers 
of variants p.Ser1108Leu and p.Arg1121Gly were identified by WES. In short, DNA from 
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the proband and family members (parents for p.Arg1121Gly and affected sibling for 
Ser1108Leu) were fragmented with covaris, captured using the Agilent SureSelect 50Mb kit 
and TruSeq adapters, pooled in groups of three samples and sequenced on an Illumina 
HiSeq2000 lane with 2x75bp reads. Fastq files were processed using the in-house ediva 
pipeline: they were aligned to the hg19 reference genome, duplicate-marked, locally 
realigned and recalibrated, and variants were called using GATK HaplotypeCaller (Van der 
Auwera, et al., 2013) followed by quality assessment with VQSR and retaining tranche 99.9. 
Variants were annotated with ediva and filtered according to familial segregation (de novo, 
recessive and X-linked variants in the trio, shared recessive and X-linked variants in the 
sibpair), MAF < 0.05% in any population/database, and scored based on functionality 
predictors. The trio case p.Arg1121Gly was also a carrier of a de novo variant in SALL3, 
while the THOC2 variant p.Ser1108Leu was the only likely candidate passing the filters in 
the sib-pair. Identified variants were further confirmed by Sanger sequencing in the carriers. 
 
p.Asn1261His (Individual 12) 
THOC2 variant was identified using the published method (Yang, et al., 2014). 
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Supplementary Figure S1. THOC2 variant amino acid residues are highly conserved. 
Amino acid sequence alignments show the variant amino acid residue (red) at the conserved 
positions (green). The amino acid sequences were aligned using www.uniprot.org/align/. 
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p.Arg77Cys                             p.Tyr517Cys 
Mutant      DISEFCEDMPS  82            Mutant       FKTFPCQHRYR 522 
Hom         DISEFREDMPS  82            Hom          FKTFPYQHRYR 522 
Mus         DISEFREDMPS  82            Mus          FKTFPYQHRYR 522 
Rattus      DISEFREDMPS  82            Rattus       FKTFPYQHRYR 522 
Pan         DISEFREDMPS  82            Pan          FKTFPYQHRYR 522 
Macaca      DISEFREDMPS  82            Macaca       FKTFPYQHRYR 522 
Canis       DISEFREDMPS  82            Canis        FKTFPYQHRYR 522 
Equus       DISEFREDMPS  82            Equus        FKTFPYQHRYR 522 
Sus         DISEFREDMPS  82            Sus          FKTFPYQHRYR 522 
Bos         DISEFREDMPS  82            Bos          FKTFPYQHRYR 522 
Loxo        DVSEFREDMPS  82            Loxo         FKTFPYQHRYR 522 
Gallus      DIIEFREDMPS  79            Gallus       FKTFPYQYRYR 519  
Xenopus     EIIAFRDDMPS  79            Xenopus      FKCFPYQYRYR 518 
    
p.Thr696Ile                            p.Gly713Asp 
Mutant      ITEEMIMEQLE 701            Mutant       QLKAEDGYFGQ 718 
Hom         ITEEMTMEQLE 701            Hom          QLKAEGGYFGQ 718 
Mus         ITEEMTMEQLE 701            Mus          QLKAEGGYFGQ 718 
Rattus      ITEEMTMEQLE 701            Rattus       QLKAEGGYFGQ 718 
Pan         ITEEMTMEQLE 701            Pan          QLKAEGGYFGQ 718 
Macaca      ITEEMTMEQLE 701            Macaca       QLKAEGGYFGQ 718 
Canis       ITEEMTMEQLE 701            Canis        QLKAEGGYFGQ 718 
Equus       ITEEMTMEQLE 701            Equus        QLKAEGGYFGQ 718 
Sus         ITEEMTMEQLE 701            Sus          QLKAEGGYFGQ 718 
Bos         ITEEMTMEQLE 701            Bos          QLKAEGGYFGQ 718 
Loxo        ITEEMTMEQLE 701            Loxo         QLKAEGGYFGQ 718 
Gallus      ITEEMTMEQLE 698            Gallus       QLKAEGGYFGQ 715 
Xenopus     ITEEMTMEQLE 697            Xenopus      QLKAEGGYFGQ 714 
 
p.Ser1108Leu                          p.Arg1121Gly 
Mutant      KLTKAPVHCLE 1113           Mutant       EYTHIGNILIV 1126 
Hom         KLTKASVHCLE 1113           Hom          EYTHIRNILIV 1126 
Mus         KLTKASVHCLE 1113           Mus          EYTHIRNILIV 1126 
Rattus      KLTKASVHCLE 1113           Rattus       EYTHIRNILIV 1126 
Pan         KLTKASVHCLE 1113           Pan          EYTHIRNILIV 1126 
Macaca      KLTKASVHCLE 1113           Macaca       EYTHIRNILIV 1126 
Canis       KLTKASVHCLE 1113           Canis        EYTHIRNILIV 1126 
Equus       KLTKASVHCLE 1113           Equus        EYTHIRNILIV 1126 
Sus         KLTKASVHCLE 1113           Sus          EYTHIRNILIV 1126 
Bos         KLTKASVHCLE 1113           Bos          EYTHIRNILIV 1126 
Loxo        KLTKASVHCLE 1113           Loxo         EYTHIRNILIV 1126 
Gallus      KLTKASVHCLE 1110           Gallus       EYTHIRNILIV 1123 
Xenopus     KLTKASVHCLE 1109           Xenopus      EYTHIRNILIV 1122 
 
p.His1187Tyr                           p.Asn1261His 
Mutant      PENEFYHKDPP 1192           Mutant       GNSGSHSNKAV 1266 
Hom         PENEFHHKDPP 1192           Hom          GNSGSNSNKAV 1266 
Mus         PENEFHHKDPP 1192           Mus          GNSGSNSNKAV 1266 
Rattus      PENEFHHKDPP 1192           Rattus       GNSGSNSNKAV 1266 
Pan         PENEFHHKDPP 1192           Pan          GNSGSNSNKAV 1266 
Macaca      PENEFHHKDPP 1192           Macaca       GNSGSNSNKAV 1266 
Canis       PENEFHHKDPP 1192           Canis        GNSSSNSSKAV 1266 
Equus       PENEFHHKDPP 1192           Equus        GNSGSNSSKAV 1266 
Sus         PENEFHHKDPP 1192           Sus          GNSGSNSSKTV 1266 
Bos         PENEFHHKDPP 1192           Bos          GNSGSNSSKTV 1266 
Loxo        PENEFHHKDPP 1192           Loxo         GNSGSTSNKTV 1266 
Gallus      PENEFHHKDPP 1189           Gallus       GNSASNSKIIK 1265 
Xenopus     PENDFHHKDPP 1188           Xenopus      GNSASSSKVLK 1264 
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Supplementary Figure S2 Brain MRI of the individual carrying the exon28: c.3503+4A>C 
THOC2 variant. Red arrow shows myelination and yellow arrow shows periventricular white 
matter lesion at age 2y 11m. 
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Supplementary Figure S3 A: THOC2 variant proteins are normally localised in HeLa and 
HEK293T cells. HeLa and HEK293T cells cultured on Poly-L-lysine coated coverslips (BD 
Biosciences) were transfected with wild type or variant Myc-THOC2 expression plasmids 
and detected by immunofluorescence using mouse anti-Myc (9E10; Sigma) primary and 
Donkey anti-rabbit-IgG Alexa 488 secondary antibody (Life Technologies). Only HeLa cell 
localisations at 630 magnification are shown. B: Nuclear and cytoplasmic (HEK293T; 
average 250 cells each) and C: nuclear and nuclear plus cytoplasmic (HeLa; average 400 
cells each) staining was visually scored and plotted. Note that nuclear plus cytoplasmic 
instead of only cytoplasmic staining for HeLa was scored because all the cells with 
cytoplasmic staining also had nuclear staining. 
A 
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Supplementary Figure 4 Children and adolescent/adults within current and previously reported* THOC2 cohorts. Images connected by vertical grey 
shading represent the same individual at different ages.  
 
Children Individual 
 
1 2 3 (twin 1) 4 (twin 2) 5 MRX12/V-
7* 
11 
Variant p.Thr696lle p.Gly713As
p 
p.His1187Tyr  p.His1187Tyr ex:28c.3503+
4A>C 
p.Leu438Pro Arg1121Gy 
ACMG 
Pathogenicity 
Classification  
De novo 
pathogenic  
De novo 
pathogenic 
Likely 
pathogenic  
Likely 
pathogenic 
Likely 
pathogenic  
Likely 
Pathogenic 
VOUS 
Age 12 5 4 4 3 - - 
 
 
 
      
Individual 
 
6 L:2_II-5* 3_twin 1 8 MRX12_V-
8* 
MRX12_V-
7* 
11 
Variant Ex35:c.445
0-2A>G 
p.lle800Thr 
 
p.His1187Tyr p.Arg77Cys p.Leu438Pro p.Leu438Pro Arg1121Gy 
Pathogenicity Likely 
pathogenic 
Likely 
pathogenic 
Likely 
pathogenic  
VOUS Likely 
pathogenic  
Likely 
pathogenic  
VOUS 
Age  10 - - 9 9 - - 
 
 
 
      
Adolescent Individual L22_III-7* L:2_II-5* D45_III-7* MRX12_V- MRX12_V- MRX12_V- 11 
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and adults  
 
 2* 8* 7* 
Variant p.lle800Thr 
 
p.lle800Thr 
 
p.Leu313phe p.Leu438Pro p.Leu438Pro p.Leu438Pro Arg1121Gy 
Pathogenicity  Likely 
pathogenic  
Likley 
Pathogenic 
VOUS Likely 
pathogenic  
Likely 
pathogenic 
Likely 
pathogenic 
VOUS 
Age 28 44 30 30 - 14  
 
     
 
 
 
Individual 
 
L33_III-3* L22_III-2* L22_III-1* MRC12_III-
17* 
MRX12_IV-
2* 
 11 
Variant p.lle800Thr 
 
p.lle800Thr 
 
p.lle800Thr 
 
p.Leu438Pro p.Leu438Pro  p.Arg1121
Gly 
Pathogenicity Likely 
pathogenic  
Likley 
pathogenic 
Likley 
pathogenic 
Likely 
pathogenic  
Likely 
pathogenic 
 VOUS 
Age 34 42 43    44 
 
     
 
 
*Previously published families (Kumar, et al., 2015). 
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Supplementary Table S1 Primers list (PCR and overlap PCR mutagenesis). 
Name 5' → 3' 
p.Tyr517Cys 
hTHOC2-1592-A1550G-R GTTTCATTCTTCCACTGGCCATACAGACGATATCTATGTTGACATGGAAATGT 
p.Ser1108Leu Mutagenesis 
hTHOC2_3302_C3323T_F ATTACAAACTAACCAAGGCATTGGTACATTGCCTTGAAACAG 
hTHOC2_3343_G3323A_R CTGTTTCAAGGCAATGTACCAATGCCTTGGTTAGTTTGTAAT 
p.His1187Tyr Mutagenesis 
hTHOC2_3537_C3559T_F CATGATACCTGAAAATGAGTTTTATCACAAGGATCCCCCTCCGAGGAAT 
hTHOC2_3585_G3559A_F ATTCCTCGGAGGGGGATCCTTGTGATAAAACTCATTTTCAGGTATCATG 
p.Asn1261His 
hTHOC2_3758_A3781C_F CAAGCAATGGAAATAGTGGATCCCACAGCAACAAAGCTGT 
hTHOC2_3797_T3781G_F ACAGCTTTGTTGCTGTGGGATCCACTATTTCCATTGCTTG 
p.Thr696Ile 
hTHOC2-2149-2088T-R CAAAATAACCACCCTCAGCTTTTAGCTGCTCTCCACCAGTCATAGCCTCTAGTTGCTCCATTaTCA 
p.Gly713Asp 
hTHOC2_2112_2138G>A_F TGGTGGAGAGCAGCTAAAAGCTGAGGATGGTTATTTTGGTCAGA 
hTHOC2-2216-R GCAAGATCATGGTCCAATAGAGCATC 
p.Arg77Cys 
hTHOC2_208_C229T_F CTTAGTGACATTAGTGAATTTtGTGAGGATATGCCCTCCATT 
hTHOC2_249_G229A_R AATGGAGGGCATATCCTCACaAAATTCACTAATGTCACTAAG 
RT-qPCR THOC2 mRNA expression 
THOC2-RT-PCR-F GAGAATGAAGGTTATGCCAAGCTGA 
THOC2-RT-PCR-R CGTGTTCTGGCCTGCATTCAAACAC 
RT-qPCR Housekeeping mRNA expression 
HPRT1/F TGACACTGGCAAAACAATGCA 
HPRT1/R GGTCCTTTTCACCAGCAAGCT 
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PCR amplification and Sanger sequencing of amplified cDNA and gDNA of carrier mother and affected son (c.4450-2A>G) 
hTHOC2-4326F TACTCCTCCACCACTGTCCAAGAG 
hTHOC2-4519-R TTGTTCCATTCTCCTCTTTACGTCTC 
PCR amplification and Sanger sequencing of amplified gDNA of normal father, carrier mother and affected son (c.3503+4A>C) 
hTHOC2-F GAATCTGGGTCAAGCTTTGG 
hTHOC2-R CTCCCATAATCTCCTGAAGG 
PCR amplification and Sanger sequencing of amplified cDNA of normal father, carrier mother and affected son (c.3503+4A>C) 
hTHOC2-ex27F GGATTTGATGGTGGAAATAAGG 
THOC2-ex30R ACAGCTTTCACACCACACTG 
  
hTHOC2-4570-R TTGGATAAGGAGATTCACAAGGAC 
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